Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Debate on Naming of Biosimilars Continues

DOI: 10.1158/2159-8290.CD-NB2015-107 Published September 2015
  • Article
  • Info & Metrics
  • PDF
Loading

When the FDA approved a biosimilar of Amgen's biologic drug Neupogen (filgrastim) in March, answering a seemingly simple question posed a decade ago became a priority: Because biosimilars aren't identical to the brand-name drugs they mimic, should they carry the same nonproprietary name?

In a letter sent to the FDA in June, the Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), and 18 other groups—including pharmacies and health care organizations—urged the agency to stick with the current international nonproprietary name (INN) system for biosimilars, a class of drugs that will grow as patents expire on biologics. Under that system, administered by the World Health Organization (WHO), the biosimilar would receive the same INN as the biologic drug it imitates.

“Adopting distinguishable names for biosimilars and biologics would erect barriers to patient access to new, more affordable medicines and could jeopardize their safety,” says David Gaugh, RPh, senior vice president of Sciences and Regulatory Affairs at the GPhA. In addition, he says, different names may confuse providers.

However, when Zarxio, a drug that helps prevent infections in patients undergoing chemotherapy, was approved, the FDA assigned it a placeholder name—filgrastim-sndz—until the agency releases a naming policy later this year.

Patient safety and reduced confusion among providers and pharmacists are also cited as arguments in favor of changing the INN system. That's why the Pharmaceutical Research and Manufacturers of America (PhRMA) advocates for a naming system that clearly identifies biologic products. Distinguishable biologic qualifiers, they argue, will improve safety tracking.

“We want to know exactly what patients are receiving,” says Jocelyn Ulrich, MPH, senior director of Science and Regulatory Advocacy at the PhRMA. Distinct names for biosimilars “will help with drug safety and help physicians with decisions regarding treatment choices.”

Under a proposal issued by the WHO in June, a biosimilar and its biologic referent would share a core INN followed by a short series of randomly assigned letters. That scheme, supported by the PhRMA but not by the GPhA, is slated to be discussed at an October WHO meeting. “If WHO does proceed with a biological qualifier, we would prefer that it be the full name of the marketing authorization holder,” says Gaugh.

Although the FDA has jurisdiction over naming in the United States, the agency generally follows WHO recommendations.

Notes

For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

  • ©2015 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 5 (9)
September 2015
Volume 5, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Debate on Naming of Biosimilars Continues
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Debate on Naming of Biosimilars Continues
Cancer Discov September 1 2015 (5) (9) 896-897; DOI: 10.1158/2159-8290.CD-NB2015-107

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Debate on Naming of Biosimilars Continues
Cancer Discov September 1 2015 (5) (9) 896-897; DOI: 10.1158/2159-8290.CD-NB2015-107
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Congress Approves Increase in Cancer Funding
  • Tasmanian Devil Facial Tumor Disease Turns Endemic
  • Proteomics Sharpens Brain Tumor Genomic Analysis
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement